ACSF3

Across TCGA pan-cancer cohorts, ACSF3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACSF3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ACSF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACSF3 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

COAD, LSCC, and LUAD are the cancer types where ACSF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.919	.013	24	view →
LSCC	DFS	Tertile	All	0.847	1.000	.001	15	view →
LUAD	OS	Quartile	All	0.892	0.675	.010	14	view →
HNSC	DFS	Median	II,III,IV	0.914	0.975	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACSF3–COAD (DFS)

Open the COAD breakdown →